SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: SKI306X, a mixed extract of three herbs, Clematis mandshurica (CM), Prunella vulgaris (PV), and Trichosanthes kirilowii (TK), is chondroprotective in animal models of osteoarthritis (OA). The objectives of this study were to investigate its effect on interleukin (IL)-1β-induced degradation of glycosaminoglycan (GAG) and the basis of its action in human OA cartilage, as well as to screen for the presence of inhibitors of matrix metalloproteinase (MMP)-13 and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)-4 in SKI306X and its component herbs, as well as in fractions from SKI306X. Methods: Human OA chondrocytes and cartilage explants were obtained during total knee replacements and incubated with IL-1β ± oncostatin M with or without SKI306X or its component herb extracts. GAG degradation was assayed in cartilage explants using a commercial kit. Expression of genes involved in cartilage destruction was measured by real-time polymerase chain reaction using chondrocyte RNA. SKI306X was fractionated by preparative liquid chromatography to test for the presence of inhibitors of MMP-13 and ADAMTS-4. Results: SKI306X and PV inhibited IL-1β-induced GAG release from cartilage explants, and SKI306X, CM, PV, and TK inhibited IL-1β-induced MMP gene expression. Unexpectedly, SKI306X greatly stimulated IL-1β + oncostatin M-induced ADAMTS-4 gene expression, probably due to its TK component. Some fractions of SKI306X also inhibited ADAMTS-4 activity. Conclusions: SKI306X and its herbal components inhibit GAG degradation and catabolic gene expression in human OA chondrocytes and cartilage explants. SKI306X likely also contains one or more ADAMTS-4 inhibitor.
Abstract
Background/Aims: SKI306X, a mixed extract of three herbs, Clematis mandshurica (CM), Prunella vulgaris (PV), and Trichosanthes kirilowii (TK), is chondroprotective in animal models of osteoarthritis (OA). The objectives of this study were to investigate its effect on interleukin (IL)-1β-induced degradation of glycosaminoglycan (GAG) and the basis of its action in human OA cartilage, as well as to screen for the presence of inhibitors of matrix metalloproteinase (MMP)-13 and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)-4 in SKI306X and its component herbs, as well as in fractions from SKI306X. Methods: Human OA chondrocytes and cartilage explants were obtained during total knee replacements and incubated with IL-1β ± oncostatin M with or without SKI306X or its component herb extracts. GAG degradation was assayed in cartilage explants using a commercial kit. Expression of genes involved in cartilage destruction was measured by real-time polymerase chain reaction using chondrocyte RNA. SKI306X was fractionated by preparative liquid chromatography to test for the presence of inhibitors of MMP-13 and ADAMTS-4. Results: SKI306X and PV inhibited IL-1β-induced GAG release from cartilage explants, and SKI306X, CM, PV, and TK inhibited IL-1β-induced MMP gene expression. Unexpectedly, SKI306X greatly stimulated IL-1β + oncostatin M-induced ADAMTS-4 gene expression, probably due to its TK component. Some fractions of SKI306X also inhibited ADAMTS-4 activity. Conclusions: SKI306X and its herbal components inhibit GAG degradation and catabolic gene expression in human OA chondrocytes and cartilage explants. SKI306X likely also contains one or more ADAMTS-4 inhibitor.
참고문헌 (21)
- Issa SN, "Epidemiology of osteoarthritis: an update", Curr Rheumatol Rep, 8, pp.7~15 (2006)
- Martel-Pelletier J, "Cartilage in normal and osteoarthritis conditions", Best Pract Res Clin Rheumatol, 22, pp.351~384 (2008)
- Goldring SR, "The role of cytokines in cartilage matrix degeneration in osteoarthritis", Clin Orthop Relat Res, 427(Suppl), pp.S27~S36 (2004)
- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines, "Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update", Arthritis Rheum, 43, pp.1905~1915 (2000)
- Cameron M, "Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: osteoarthritis", Phytother Res, 23, pp.1497~1515 (2009)
- Choi JH, "Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model", Osteoarthritis Cartilage, 10, pp.471~478 (2002)
- Kim JH, "SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture", J Pharmacol Sci, 98, pp.298~306 (2005)
- Hartog A, "The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators", Phytomedicine, 15, pp.313~320 (2008)
- Jung YB, "Effect of SKI 306X, a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee: a double-blind placebo controlled study", Am J Chin Med, 29, pp.485~491 (2001)
- Lung YB, "A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee", Am J Chin Med, 32, pp.291~301 (2004)
- Billinghurst RC, "Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage", J Clin Invest, 99, pp.1534~1545 (1997)
- Song YW, "Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial", Clin Ther, 29, pp.862~873 (2007)
- Uitterlinden EJ, "Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants", Osteoarthritis Cartilage, 14, pp.250~257 (2006)
- Koshy PJ, "The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction", Arthritis Rheum, 46, pp.961~967 (2002)
- Wachsmuth L, "ADAMTS-1, a gene product of articular chondrocytes in vivo and in vitro, is downregulated by interleukin 1beta", J Rheumatol, 31, pp.315~320 (2004)
- Rogerson FM, "Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice", Arthritis Rheum, 62, pp.3365~3373 (2010)
- Lauer-Fields JL, "Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate", Anal Biochem, 373, pp.43~51 (2008)
- Fosang AJ, "Drug insight: aggrecanases as therapeutic targets for osteoarthritis", Nat Clin Pract Rheumatol, 4, pp.420~427 (2008)
- Lauer-Fields JL, "High throughput screening of potentially selective MMP-13exosite inhibitors utilizing a triple-helical FRET substrate", Bioorg Med Chem, 17, pp.990~1005 (2009)
- Li NG, "New hope for the treatment of osteoarthritis through selective inhibition of MMP-13", Curr Med Chem, 18, pp.977~1001 (2011)
- Verma P, "ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis", J Cell Biochem, 112, pp.3507~3514 (2011)